S. aureus is one of the bacteria most commonly isolated from intramammary infections (IMIs) in cows (Tenhagen et al., 2006) and is responsible for about 35% of economic losses due to mastitis (Fox and Hancock, 1989) . Infections of S. aureus have often proven resistant to treatment and antimicrobial therapy during lactation generally results in low clinical cure rates (Luby et al., 2007) . One reason for the poor clinical cure rates could be the intracellular location of S. aureus, such as in epithelial cells or macrophages, and its ability to survive antibiotic treatments (Tuchscherr et al., 2011) . Consequently, antibiotic therapy is often ineffective in eliminating chronic udder S. aureus infections (Pellegrino et al., 2008) . Furthermore, regulatory methods tend to limit the use of antibiotics in dairy cattle to reduce their residues in milk. Thus, it is important to search for novel therapeutic approaches to eliminate intramammary S. aureus infections.
Nisin is an antimicrobial peptide with 34 amino acids synthesized by Lactococcus lactis (Carr et al., 2002) , and has been proven to have inhibitory effects on many Gram-positive bacteria such as mastitis pathogens. It has been licensed as a food preservative in 48 countries (Deegan et al., 2006) due to its effective antibacterial activity and safety for human consumption. We have previously shown that nisin can be successfully used to treat both clinical and subclinical mastitis in lactating cows Wu et al., 2007) . In addition, vaccination with S. aureus bacterin has improved antibiotic therapy of S. aureus IMIs (Steele and McDougall, 2014) .
The aim of this study was to determine if vaccination against S. aureus potentiates nisin treatment of subclinical S. aureus IMI in lactating cows. Changes in IMI, SCC, NAGase activity, and protein and fat contents in milk were analyzed before and after nisin treatment.
Materials and methods

Cows
The experimental dairy farm, with about 1000 Holstein dairy cows, was situated in the suburban area of Hangzhou, Zhejiang, China. The animals were milked by machine three times per day. Cows with milk SCCs of ≥5×10 5 cells/ml were considered to have mastitis. A total of 75 cows with at least one quarter subclinically infected with S. aureus were used.
Nisin
The nisin Z used in this study was in the form of a purified product (1.80×10 4 IU/mg) produced by the Zhejiang Silver-Elephant Bio-Engineering Co., Ltd., Tiantai, Zhejiang, China. Before treatment, the nisin (2.50×10 6 IU) was dissolved in 20 ml of sterile physiological saline solution.
Formulation of S. aureus bacterin
The bacterin was prepared using S. aureus CQ399RP strain isolated from a mastitis case on the farm where this study was performed, and the bacteria were incubated in brain-heart infusion broth with aeration at 37 °C for 18 h. The cells were inactivated with formalin (0.4%, v/v) at 4 °C for 24 h, and resuspended in saline (9 g/L NaCl, pH 7.0). Two washings were performed by centrifuging the inactivated bacteria in saline at 6000 r/min for 30 min at 4 °C. Each 2-ml dose contained 4×10 10 CFU/ml of S. aureus. Thimerosal was added as preservative at a final concentration of 0.11 g/L. Aluminum hydroxide (35 g/L) and ginseng extract (0.25 g/L) were added as an adjuvant. Complete inactivation of the bacterin was confirmed by inoculating the bacterin on blood agar and incubating for 24 to 48 h at 37 °C.
Treatment
Cows infected with S. aureus were randomly allocated to one of three groups (25 cows per group). In group I, cows were intramammarily infused with 2.50×10 6 IU of nisin Z once daily for three days. The dose of nisin Z was chosen based on the results of a study by Wu et al. (2007) . They infused three different doses of nisin Z (1.25×10 6 , 2.50×10 6 , and 5.00×10 6 IU) into mammary glands and showed that 2.50×10 6 IU was the optimal dose. One week before and one week after nisin treatment, 2 ml of S. aureus bacterin was injected into the supramammary lymph node. In group II, cows received the same nisin treatment as in group I, but no bacterin. Group III was untreated and used as a control group. Before intramammary infusion, the affected quarter was completely milked out and the teat end was disinfected with a cotton swab soaked in 75% (v/v) alcohol.
Collection and analysis of milk samples
Before starting and at 2, 4, and 6 weeks after terminating treatment, milk was aseptically sampled from the affected mammary quarters for bacteriological examination and analyses of milk SCC, NAGase activity, and protein and fat contents.
Bacteriological examination
Each milk sample was inoculated on a blood agar plate and the plate was incubated at 37 °C for 24 to 48 h. After that, bacterial growth was observed for primary isolation. If three or more different colony patterns of bacteria were found, the milk sample was assumed to be contaminated and was discarded. Then a single colony was selected on the blood agar, inoculated into broth medium, and incubated at 37 °C for 18 to 24 h. Specific bacterial species, such as staphylococci, streptococci, and Gram-negative bacteria, were identified according to the procedures described by the Laboratory and Field Handbook on Bovine Mastitis, National Mastitis Council, Inc., Arlington, VA, USA.
Somatic cell count analysis
Milk samples were preserved using bronopol (2 μl/ml) and FOSSmatic™ Minor (Foss Electric, Hillerød, Denmark) was used to determine SCC.
NAGase test
Three cycles of freezing and thawing of milk samples were performed to release NAGase from cells, and the samples were then centrifuged for 20 min at 3500 r/min to get rid of the cream. Acetic acid (10%, v/v) was added to the skim milk to adjust the pH to 4.6, and the samples were centrifuged for 20 min at 3500 r/min to obtain whey. A commercial kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China) was used to determine NAGase activity according to the manufacturer's protocols. The optical density (OD) value of paranitrophenol was analyzed in triplicate at a wavelength of 400 nm during the reaction (at 37 °C) between the 4-methylumbelliferyl-N-acetyl-β-glucosaminide substrate and the NAGase. The amount of paranitrophenol released from 1 L of whey at 37 °C in 15 min was expressed as one unit of NAGase activity.
Analysis of milk protein and fat contents
Integrated Milk Testing MilkoScan FT6000 (Foss Electric, Hillerød, Denmark) was used to determine milk protein and fat contents.
Statistical analysis
Statistical analysis was performed using SPSS (Version 20.0, Chicago IL, USA). A χ 2 test was used to compare the number of quarters with an SCC of ≥5×10 5 cells/ml among groups at each sampling time, the number of quarters with an SCC of ≥5×10 5 cells/ml and the number of IMIs between pre-and posttreatments within a group. Analysis of variance was performed to compare NAGase activities, milk protein and fat contents among the three groups at each sampling occasion and between pre-and post-treatment times within the same group. The level of significance was set at P<0.05.
Results
Intramammary infections and somatic cell count
Bacteriological cure rates were 68.0%, 72.0%, and 72.0%, respectively, when milk samples were examined at 2, 4, and 6 weeks after treatment in group I (Table 1) , and were 44.0%, 40.0%, and 40.0%, respectively, in group II. No change was detected in the control group throughout the experiment. Compared with the control group, both treated groups showed significantly reduced IMIs, and there were significantly fewer infected quarters in group I than in group II.
Table 1 also shows that the number of quarters with an SCC of ≥5×10 5 cells/ml significantly decreased after nisin or nisin-bacterin treatment, but was unchanged in the control group. Table 2 shows that NAGase activity significantly decreased after nisin or nisin-bacterin treatment while no significant changes were found in the control group.
NAGase activity
Protein and fat contents
In group I, milk protein increased significantly from (2.86±0.14)% to (3.08±0.18)%, (3.08±0.19)%, and (3.07±0.19)% at 2, 4, and 6 weeks after treatment, respectively, and milk fat significantly increased from (2.99±0.11)% to (3.18±0.15)%, (3.25±0.19)%, and (3.26±0.18)%, respectively. In group II, milk protein significantly increased from (2.84±0.18)% to (2.98± 0.25)%, (3.02±0.23)%, and (3.01±0.21)%, respectively, at 2, 4, and 6 weeks after treatment, and milk fat increased significantly from (2.99±0.16)% to (3.13±0.21)%, (3.17±0.24)%, and (3.21±0.27)%, respectively. No changes were found for milk protein ((2.83±0.09)%, (2.80±0.10)%, (2.81±0.09)%, and (2.80±0.10)%, respectively) or milk fat ((2.96±0.12)%, (2.98±0.12)%, (3.01±0.11)%, and (3.01±0.10)%, respectively) before treatment and 2, 4, and 6 weeks after treatment in the control group.
Discussion
Because of the failure of chemotherapy for treating S. aureus mastitis and the problems associated with antibiotic residues in milk, antibiotic treatment is usually not recommended during the lactating period. We previously successfully treated subclinical IMIs in lactating cows using nisin Z, resulting in a cure rate of 50% for S. aureus infection . Similar results were obtained in the present study in which the bacteriological cure rate for S. aureus was about 40%-44%. The main advantage of using nisin as an antimicrobial agent to treat mastitis is its safety compared with conventional antibiotics. In the present study, nisin treatment was improved by immunization with S. aureus bacterin in the supramammary lymph node. The bacteriological cure rate was significantly higher in the nisin-bacterin group (68%-72%) than in the nisin group (40%-44%).
IMI is the major factor inducing high milk SCCs (González-RodríGuez et al., 1995) . A high SCC is usually taken as an indicator of an IMI caused by bacteria, and a low SCC (<1.50×10 5 cells/ml) in general implies freedom from such infections (Sordillo et al., 1997) . We previously demonstrated that the number of quarters with high milk SCCs (≥5×10 5 cells/ml) was significantly reduced by nisin treatment. In the present study, fewer quarters with high milk SCCs (≥5×10 5 cells/ml) were found in nisin-bacterin-treated cows than in the nisin-only group. Fewer quarters of high milk SCCs paralleled significantly reduced milk NAGase activity after treatment in both treated groups compared with the control or pre-treatment values.
Mastitis causes injury to milk secretory cells in the mammary gland and decreases the synthesis of fat and protein (Ogola et al., 2007) . Therefore, the ability of the mammary epithelium to synthesize and secrete the major specific milk constituents is reduced (Fox et al., 1985) . In this study, the contents of protein and fat increased significantly after nisin or nisin-bacterin treatment compared to the control or pre-treatment values. This may be attributed to accelerated regeneration of the mammary epithelium after treatment. Milk production might also benefit from the regenerated mammary epithelium. However, the quantity of milk produced was not recorded because the milking machine lacked the capability to record milk production from individual cows.
The use of a vaccine in combination with an antimicrobial agent to treat IMIs in lactating cows is not new. Smith et al. (2006) treated 20 dairy cows with chronic intramammary S. aureus infections by vaccination with a polyvalent S. aureus bacterin along with intramammary administration of pirlimycin. Significantly more S. aureus infections were eliminated from treated cows, compared with control cows. Recently, Czernomysy-Furowicz et al. (2014) treated 15 cows with S. aureus IMI by vaccination with an anti-S. aureus herd-specific autovaccine combined with intramammary infusion of cefuroxime and obtained prolonged udder protection against bacterial infection. In the present study, nisin was used as an antibacterial agent. Nisin has been reported to destroy bacteria by interaction with anionic lipids and formation of pore complexes on the cytoplasmic membrane of the bacterial cells (Tong et al., 2014) . Immunization of mastitis vaccine at this site may trigger the synthesis of large amounts of opsonizing IgG for phagocytosis of S. aureus by neutrophils (Nordhaug et al., 1994) . The results found in group I could be due to the combined effects of nisin treatment and bacterin vaccination.
In conclusion, vaccination with S. aureus bacterin in the supramammary lymph node potentiated intramammary infusion of nisin for the treatment of subclinical intramammary S. aureus infections in lactating cows. When compared to the nisin-treated group, nisin-bacterin treatment significantly reduced intramammary S. aureus infections, reduced the number of quarters with high milk SCCs, and increased milk protein and fat contents. The major limitation of this study is that it was carried out on a medium-sized herd. To prove the effectiveness of nisin-bacterin treatment, the method should be tested on a large herd in which subclinical mastitis gives rise to high bulk milk SCCs over the upper limit.
